Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Johnson and Johnson
Colorcon
McKesson
Medtronic

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Epelsiban

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Epelsiban?

Epelsiban is an investigational drug.

There have been 4 clinical trials for Epelsiban. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2016.

The most common disease conditions in clinical trials are Adenomyosis and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline and [disabled in preview].

There are eight US patents protecting this investigational drug and sixty-one international patents.

Recent Clinical Trials for Epelsiban
TitleSponsorPhase
Placebo-controlled Proof of Concept Study of Epelsiban in Women With AdenomyosisGlaxoSmithKlinePhase 2
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women VolunteersGlaxoSmithKlinePhase 1
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female VolunteersGlaxoSmithKlinePhase 1

See all Epelsiban clinical trials

Clinical Trial Summary for Epelsiban

Top disease conditions for Epelsiban
Top clinical trial sponsors for Epelsiban

See all Epelsiban clinical trials

US Patents for Epelsiban

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Epelsiban   Start Trial Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies Ferring B.V. (Hoofddorp, NL)   Start Trial
Epelsiban   Start Trial Piperazinediones as oxytocin receptor antagonists Glaxo Group Limited (Greenford, Middlesex, GB)   Start Trial
Epelsiban   Start Trial Compounds Glaxo Group Limited (Greenford, Middlesex, GB)   Start Trial
Epelsiban   Start Trial Compounds Glaxo Group Limited (Greenford, Middlesex, GB)   Start Trial
Epelsiban   Start Trial Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-- (4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione Glaxo Group Limited (Brentford, Middlesex, GB)   Start Trial
Epelsiban   Start Trial Compounds Glaxo Group Limited (Brentford, Middlesex, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Epelsiban

Drugname Country Document Number Estimated Expiration Related US Patent
Epelsiban Australia 2015367900 2034-12-22   Start Trial
Epelsiban Brazil 112017013521 2034-12-22   Start Trial
Epelsiban Canada 2971846 2034-12-22   Start Trial
Epelsiban Chile 2017001640 2034-12-22   Start Trial
Epelsiban China 107249618 2034-12-22   Start Trial
Epelsiban Eurasian Patent Organization 201791361 2034-12-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Mallinckrodt
Dow
Moodys
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.